Article Figures & Data
Tables
Trial Patient Population Endpoint Event Rate Combination (%) Event Rate Monotherapy (%) P CHARISMA (3) CAD CV death, MI, or CVA at 28 months 6.8 7.3 .22 MATCH (5) CVA CVA, MI, CV death, or CV hospitalization at 18 months 15.7 16.7* .244 CLARITY (6) STEMI Occlusion, death, or recurrent MI at 8 days 15 21.7 <.001 CURE (9) NSTEMI CV death, MI, or CVA at 12 months 9.3 11.4 <.001 PCI-CURE (12) NSTEMI with PCI CV death or MI at 8 months 8.8 12.6 .002 CREDO (11) PCI Death, MI, or CVA at 12 months 8.5 11.5 .02 * Clopidogrel monotherapy.
CHARISMA, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance; MATCH, Management of Atherothrombosis with Clopidogrel in High-Risk Patients; CLARITY, Clopidogrel as Adjunctive Reperfusion Therapy; CURE, Clopidogrel in Unstable Angina to Prevent Recurrent Events; PCI-CURE, Percutaneous Coronary Intervention in the Clopidogrel in Unstable Angina to Prevent Recurrent Events; CREDO, Clopidogrel for the Reduction of Events During Observation; CAD, coronary artery disease; CVA, cardiovascular accident; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; CV, cardiovascular; MI, myocardial infarction.
Trial Patient Population Duration (months) Major and Minor Bleeds Combination Therapy (%) Monotherapy (%) CURE (9) NSTEMI 9 8.8 5.1 CREDO (11) PCI 12 14.1 12.3 CHARISMA (3) CAD 28 3.8 2.6 MATCH (5) CVA 18 5.1 1.6* TRITON (2) ACS with PCI 15 5.0†/3.8 NA * Clopidogrel monotherapy.
† Prasugrel plus aspirin.
CURE, Clopidogrel in Unstable Angina to Prevent Recurrent Events; CREDO, Clopidogrel for the Reduction of Events During Observation; CHARISMA, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance; MATCH, Management of Atherothrombosis with Clopidogrel in High-Risk Patients; TRITON, Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel; NSTEMI, non-ST-segment elevation myocardial infarction; CAD, coronary artery disease; CVA, cardiovascular accident; ACS, acute coronary syndrome; PCI, percutaneous coronary intervention.
Indication Duration SORT Primary prevention of cardiovascular events Avoid B Secondary prevention of stroke Avoid B ACS, without stent 1–12 months A Bare-metal stent 1–12 months A Drug-eluting stent 12 months C SORT, strength of recommendation taxonomy,25 ACS, acute coronary syndrome.
In this issue
Jump to section
Related Articles
Cited By...
- Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a ''target trial
- Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating ''target trials (the ADAPTT Study)
- Optimism: A Good Theme for Family Medicine